TY - JOUR
T1 - Urothelial Carcinoma in Situ of the Bladder with Glandular Differentiation
AU - Yang, Zhiming
AU - Epstein, Jonathan I.
N1 - Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Urothelial carcinoma in situ (CIS) of the bladder with glandular differentiation (CIS-GL) is rare with some showing an association with small cell carcinoma. There is a paucity of data on whether CIS-GL diagnosed in the absence of invasive carcinoma is associated with an increased risk of developing small cell carcinoma of the bladder. Twenty-seven cases of CIS-GL were identified from the consult files of one of the authors from 2008 to 2015 without prior or coexisting invasive carcinoma at the time of diagnosis. Sixty-five additional cases were identified with concurrent CIS-GL and invasive carcinoma to assess the nature of the association. Of the 27 cases with only CIS-GL without invasive carcinoma at the time of diagnosis, follow-up time ranged from 11 to 91 months (mean, 41.1 mo). Of 24/27 cases with follow-up information: 13 (54.2%) had no evidence of disease at last follow-up, typically treated with induction and maintenance Bacillus Calmette-Guerin; 3 (12.5%) patients underwent radical cystectomy due to disease progression; 2 (8.3%) patients had recurrent CIS, and 1 (4.2%) had recurrent noninvasive low-grade papillary urothelial carcinoma (UC) (these patients underwent transurethral resection of the bladder and Bacillus Calmette-Guerin treatment); 2 (8.3%) patients died of metastatic UC; and 3 (12.5%) died of other or unknown causes. Of note, none of these 24 patients developed small cell carcinoma. Of the 65 cases with concurrent CIS-GL and invasive carcinoma, the invasive carcinoma was: pure UC in 29/65 (45%); invasive UC with GL in 13/65 (20%); coexisting small cell carcinoma and invasive UC in 8/65 (12%); plasmacytoid UC in 7/65 (11%); sarcomatoid UC in 3/65 (5%); micropapillary UC in 2/65 (3%); squamous in 2/65 (3%); and signet ring with colloid features in 1/65 (1%). Patients with CIS-GL without invasive carcinoma are at significant risk for cancer progression and in a minority of cases at risk for death from bladder carcinoma, similar to usual CIS. Typically, subsequent invasive carcinoma is UC rather than adenocarcinoma. Similarly, the largest fraction of concurrent invasive carcinoma and CIS-GL is UC. However, this study for the first time demonstrates the wide spectrum of other UC variants that coexist with CIS-GL, including a sizeable minority of cases with invasive UC with GL. Although there is a disproportionately high fraction of CIS-GL with coexisting small cell carcinoma, small cell carcinoma does not seem to develop at high frequency following the diagnosis and treatment of CIS-GL.
AB - Urothelial carcinoma in situ (CIS) of the bladder with glandular differentiation (CIS-GL) is rare with some showing an association with small cell carcinoma. There is a paucity of data on whether CIS-GL diagnosed in the absence of invasive carcinoma is associated with an increased risk of developing small cell carcinoma of the bladder. Twenty-seven cases of CIS-GL were identified from the consult files of one of the authors from 2008 to 2015 without prior or coexisting invasive carcinoma at the time of diagnosis. Sixty-five additional cases were identified with concurrent CIS-GL and invasive carcinoma to assess the nature of the association. Of the 27 cases with only CIS-GL without invasive carcinoma at the time of diagnosis, follow-up time ranged from 11 to 91 months (mean, 41.1 mo). Of 24/27 cases with follow-up information: 13 (54.2%) had no evidence of disease at last follow-up, typically treated with induction and maintenance Bacillus Calmette-Guerin; 3 (12.5%) patients underwent radical cystectomy due to disease progression; 2 (8.3%) patients had recurrent CIS, and 1 (4.2%) had recurrent noninvasive low-grade papillary urothelial carcinoma (UC) (these patients underwent transurethral resection of the bladder and Bacillus Calmette-Guerin treatment); 2 (8.3%) patients died of metastatic UC; and 3 (12.5%) died of other or unknown causes. Of note, none of these 24 patients developed small cell carcinoma. Of the 65 cases with concurrent CIS-GL and invasive carcinoma, the invasive carcinoma was: pure UC in 29/65 (45%); invasive UC with GL in 13/65 (20%); coexisting small cell carcinoma and invasive UC in 8/65 (12%); plasmacytoid UC in 7/65 (11%); sarcomatoid UC in 3/65 (5%); micropapillary UC in 2/65 (3%); squamous in 2/65 (3%); and signet ring with colloid features in 1/65 (1%). Patients with CIS-GL without invasive carcinoma are at significant risk for cancer progression and in a minority of cases at risk for death from bladder carcinoma, similar to usual CIS. Typically, subsequent invasive carcinoma is UC rather than adenocarcinoma. Similarly, the largest fraction of concurrent invasive carcinoma and CIS-GL is UC. However, this study for the first time demonstrates the wide spectrum of other UC variants that coexist with CIS-GL, including a sizeable minority of cases with invasive UC with GL. Although there is a disproportionately high fraction of CIS-GL with coexisting small cell carcinoma, small cell carcinoma does not seem to develop at high frequency following the diagnosis and treatment of CIS-GL.
KW - carcinoma in situ
KW - small cell carcinoma
KW - urothelial carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85048739477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048739477&partnerID=8YFLogxK
U2 - 10.1097/PAS.0000000000001073
DO - 10.1097/PAS.0000000000001073
M3 - Article
C2 - 29683821
AN - SCOPUS:85048739477
SN - 0147-5185
VL - 42
SP - 971
EP - 976
JO - American Journal of Surgical Pathology
JF - American Journal of Surgical Pathology
IS - 7
ER -